e-med-isral-ribbon

Study Reports Pain-Free Status for Zomig-ZMT as Early as One Hour After Treatment

SEATTLE, WA — June 21, 2002 —

Data presented today at the 44th Annual Scientific Meeting of the American Headache Society (AHS) show that Zomig-ZMT (zolmitriptan) 2.5 mg Orally Disintegrating Tablets achieve pain-free status as early as 1 hour after treatment increasing up to 2 hours, with sustained pain relief for as long as 24 hours.

(1) Zomig-ZMT, a product of AstraZeneca Pharmaceuticals LP, is available in both 2.5 and 5.0 mg dosages in an orange-flavored tablet that dissolves on the tongue in seconds. “Achieving pain-free status is a clinically important measure of a migraine therapy’s effectiveness,” said Elizabeth Loder, M.D., Clinical Associate in Medicine at Massachusetts General Hospital in Boston, and principle investigator of the study.

 “This new study, one of the few clinical trials to look at pain-free response as a primary endpoint, shows that patients may be able to attain freedom from the painful, debilitating symptoms of a migraine with a convenient formulation.” Zomig-ZMT was introduced in May 2001 as an additional formulation of Zomig® (zolmitriptan), part of the newest class of migraine medications called “triptans.” Zomig-ZMT rapidly dissolves on the tongue, without the need for additional fluids. The formulation is made up of water-soluble ingredients that disperse quickly when placed in the mouth.

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים

© ‫ אי-מד שיווק רפואי בע”מ
 כל הזכויות שמורות
09-765-8233 

 

הנך גולש/ת באתר כאורח/ת.

במידה והנך מנוי את/ה מוזמן/ת לבצע כניסה מזוהה וליהנות מגישה לכל התכנים המיועדים למנויים
עדיין לא מנוי/ה ונמנה/ת על הצוות הרפואי? מוזמן/ת לבצע הרשמה כאן
להרשמה לאתר
להמשך גלישה כאורח סגור חלון זה